Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effects of Losartan Potassium on Brain Tumors in Patients with Glioblastoma or Brain Metastases from Non-Small-Cell Lung Cancer

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of the medication losartan on certain types of brain tumors. The diseases being studied include glioblastoma, which is a type of brain cancer, and brain metastases from non-small-cell lung cancer (NSCLC). The treatment involves using different doses of Cozaar, which contains the active ingredient losartan potassium, available in 12.5 mg, 50 mg, and 100 mg film-coated tablets. The purpose of the study is to understand how losartan affects blood flow and the pressure caused by solid stress in brain tumors.

Participants in the study will take the medication orally over a period of time, and their progress will be monitored through various medical imaging techniques, such as MRI (Magnetic Resonance Imaging). These imaging techniques help in assessing changes in blood flow and the physical stress within the tumors. The study aims to observe how the tumors respond to the medication over time, with regular check-ups and imaging sessions scheduled throughout the study period.

The study will also track changes in the participants' neurological performance and quality of life, using established scoring systems like the Karnofsky Performance Score (KPS) and the Eastern Cooperative Oncology Group (ECOG) scores. Additionally, the study will monitor the overall survival rates and any side effects experienced by participants during the treatment. The trial is expected to continue until the end of 2025, providing valuable insights into the potential benefits of losartan for patients with these specific brain tumors.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, eligibility is confirmed based on specific criteria, including age, medical history, and ability to undergo MRI exams.

    Participants must have a confirmed diagnosis of either glioblastoma or brain metastases from non-small-cell lung cancer.

  2. Step 2

    Baseline assessment

    Initial assessments include MRI scans to measure brain tumor characteristics and blood tests to evaluate organ function.

    These assessments establish a baseline for future comparisons.

  3. Step 3

    Medication administration

    Participants receive losartan, an oral medication, in the form of film-coated tablets.

    Dosages include 12.5 mg, 50 mg, or 100 mg, depending on individual requirements and study protocol.

  4. Step 4

    Treatment schedule

    The treatment involves taking losartan daily, with dosage adjustments as needed based on response and tolerance.

    Regular follow-up visits are scheduled to monitor progress and adjust treatment as necessary.

  5. Step 5

    Follow-up assessments

    Follow-up MRI scans are conducted at specified intervals to assess changes in brain tumor perfusion and solid stress.

    These intervals include days 14-16, 28-30, and 42-44 for glioblastoma patients, and days 90-14, 180-14, and 270-14 for patients with brain metastases.

  6. Step 6

    Evaluation of outcomes

    Primary outcomes focus on changes in brain blood flow and solid stress, measured through MRI.

    Secondary outcomes include changes in neurological performance, quality of life, and overall survival rates.

  7. Step 7

    Completion of study

    The study is expected to conclude by December 31, 2025, with final assessments and data analysis.

    Participants' overall health and treatment responses are evaluated to determine the effectiveness of losartan in managing brain tumors.

Who can join the trial?

13 criteria

  • Have a confirmed diagnosis of **glioblastoma** (a type of brain tumor) or at least one confirmed brain metastasis from **non-small-cell lung cancer**.
  • Provide documentation on specific genetic markers related to the disease, such as **MGMT promoter methylation** and **IDH gene mutation** (for glioblastoma patients only).
  • Have organ functions that are strong enough to handle the study treatment, as determined by the study doctor.
  • If a female patient can have children, she must use highly effective birth control methods and avoid pregnancy during the study and for at least 14 days after the last dose.
  • Be able to understand and willing to sign a consent form agreeing to participate in the study.
  • Be able to undergo an **MRI exam**, which is a type of scan that uses a contrast agent to help see the brain more clearly.
  • Have a measurable brain tumor, meaning it can be accurately measured using an MRI scan.
  • Be at least 18 years old.
  • Be eligible to receive the study drug **losartan** according to the study rules and the doctor's assessment.
  • Have an **ECOG performance status** of 2 or less, which means being able to carry out daily activities with some limitations.
  • Have a life expectancy of more than 3 months from the start of treatment.
  • Have a history of brain surgery if participating in the glioblastoma study.
  • Be scheduled for treatments like chemotherapy, radiotherapy, or surgery, depending on the specific study group.

Who cannot join the trial?

10 criteria

  • Patients with other types of cancer that are not specified in the study.
  • Patients who have had previous treatment that might interfere with the study results.
  • Patients with severe medical conditions that could make participation unsafe.
  • Patients who are unable to follow the study procedures or instructions.
  • Patients who are pregnant or breastfeeding.
  • Patients who are participating in another clinical trial at the same time.
  • Patients with allergies to the study medication or its ingredients.
  • Patients who have had a recent major surgery.
  • Patients with uncontrolled high blood pressure.
  • Patients with severe liver or kidney disease.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Losartan is a medication used in this study to explore its effects on blood flow and mechanical stress in brain tumors. It works by blocking certain receptors in the body, which can help relax blood vessels and improve circulation. The study aims to understand how different amounts of losartan can influence these factors in patients with brain tumors.

What is already known about the treatment

Losartan – Losartan is administered orally in tablet form and is currently being studied for its effects on brain tumors, specifically in cases of brain metastases from non-small-cell lung cancer and glioblastoma. It is an angiotensin II receptor blocker, commonly used to treat high blood pressure, but in this study, it is being evaluated for its potential to improve blood flow and reduce mechanical stress in brain tumors. The medication works by blocking the action of angiotensin II, a chemical in the body that causes blood vessels to tighten, thereby helping to relax and widen blood vessels. This study aims to understand how different doses of Losartan affect blood flow and stress in brain tumors.

Investigated diseases

  • Brain metastases from non-small-cell lung cancer (NSCLC)

    This condition occurs when cancer cells from a primary lung tumor spread to the brain. The metastases can cause various neurological symptoms depending on their size and location in the brain. As the disease progresses, these symptoms may worsen, potentially affecting cognitive and motor functions. The growth of these metastases can lead to increased pressure within the skull, causing headaches and other related symptoms. The progression of brain metastases can vary, with some growing rapidly while others remain stable for a period.

  • Glioblastoma

    Glioblastoma is an aggressive type of brain tumor that originates from glial cells. It is characterized by rapid growth and a tendency to infiltrate surrounding brain tissue, making it challenging to manage. Newly diagnosed glioblastomas often present with symptoms such as headaches, seizures, and neurological deficits. Recurrent glioblastomas are those that return after initial treatment, often with more aggressive behavior. The tumor's progression can lead to increased intracranial pressure and worsening neurological symptoms. Glioblastomas are known for their heterogeneity, meaning they can vary significantly in their cellular composition and behavior.

Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-507575-22-00Estimated enrolment153 patientsSponsorOslo University Hospital HF

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.